CSI Market
Sign In | Register

Arrowhead Pharmaceuticals Inc (ARWR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ARWR Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Arrowhead Pharmaceuticals Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
9 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-288.25
Depreciation & amortization37.52
Amortization of Other Assets2.72
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total19.00
Share-based Compensation51.13
Income (Loss) from Equity Method Investments-9.19
Paid-in-Kind Interest44.37
Gain Loss From Sale Of Subsidiary-
Gain On Acquisition-
Stock Issued As Gift-
Stock Issued For In Process Research And Development-
Gain Loss On Sale Of Stock In Subsidiary-
Noncontrolling Interest-
Provision For Allowance For Bad Debts And Sales Related Allowances-
Non Cash Gain In Equity Investment-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Investment Income Amortization Of Premium-
Property And Equipment Purchased Through Tenant Improvement Allowance Financing-
Gain Loss On Treasury Stock Settlement-
Noncash Transfer Of Property And Equipment To Affiliate0.56
Increase Decrease In Contract With Customer Liability154.76
Increase Decrease In Operating Lease Liability-2.42
Increase Decrease In Operating Lease Liability-2.42
Income taxes0.00
Realized Investment Gains (Losses), Total0.04
Increase (Decrease) in Accounts Receivable1.91
Increase (Decrease) in Accounts Payable9.98
Increase (Decrease) in Accrued Liabilities-15.21
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets29.94
Other Working Capital2.45
Other Noncash Income (Expense)0.00
Other net7.96
Payments for (Proceeds from) Other Operating Activities26.09
Discontinued operations0.00
Net Cash flow from Operating Activities-79.55
Investing Activities
Capital Expenditures-8.57
Sale of Capital Items0.00
Short-term Investments Proceeds272.94
Payments to Acquire Available-for-sale Securities, Debt-1,138.71
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Cash Divested from Deconsolidation0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-874.34
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-66.60
Long-term debt - borrowings700.00
Long-term debt - repayments-117.89
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock12.76
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock100.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net190.68
Proceeds From Sale Of Stock In Subsidiary-
Proceeds From Exercise Of Warrants And Stock Options-
Proceeds From Exercises Of Warrants And Stock Options-
Proceeds From Sale Of Future Royalties-
Proceeds From Tenant Improvement Allowance-
Payments of Ordinary Dividends, Noncontrolling Interest-38.43
Dividends paid0.00
Net Cash Flow from Financing Activities780.52
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-88.11
Total Cash Flow-173.37
4 historic quarters locked

Sign in to unlock the full Arrowhead Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Arrowhead Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000879407-26-000057

Figures are derived from filed reports and may be restated. Historical data is subject to revision.